Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program
Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.
